Adi Laser-Azogui
Research Subjects
Adi Laser-Azogui has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Alaa Awad
Baruch Padeh—Tzafon Medical Center, Affiliated with the Azrieli Faculty of Medicine, Bar-Ilan University, Zefad 1528001, Israel
1 shared publication - Lina Abzah
Baruch Padeh—Tzafon Medical Center, Affiliated with the Azrieli Faculty of Medicine, Bar-Ilan University, Zefad 1528001, Israel
1 shared publication - Michal Mark Danieli
EARLY O.M. Ltd., Netanya 4250363, Israel
1 shared publication - Ory Wiesel
Baruch Padeh-Tzafon Medical Center, Poriya 1528001, Israel
1 shared publication - Tatiyana Suharev
EARLY O.M. Ltd., Netanya 4250363, Israel
1 shared publication
Latest Publications
- Open Access
- 16 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (20) , 6164
The Potential Benefit of a Novel Urine Biosensor Platform for Lung Cancer Detection in the Decision-Making Process: From the Bench to the Bedside
Background: Lung cancer is the leading cause of cancer-related mortality worldwide. Lung cancer screening and early detection resulted in a decrease in cancer-specific mortality; however, it introduced additional dilemmas and adherence barriers for patients and providers. Methods: Innovations such as biomolecular diagnosis and biosensor-based technology improve the detection and stratification of high-risk patients and might assist in overcoming adherence barriers, hence providing new horizons for better selection of screened populations. Conclusions: In the present manuscript, we discuss some of the dilemmas clinicians are currently facing during the diagnosis and treatment processes. We further highlight the potential benefits of a novel biosensor platform for lung cancer detection during the decision making process surrounding lung cancer.
- 16 October 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (20) , 6164
Open AccessThe Potential Benefit of a Novel Urine Biosensor Platform for Lung Cancer Detection in the Decision-Making Process: From the Bench to the Bedside
Background: Lung cancer is the leading cause of cancer-related mortality worldwide. Lung cancer screening and early detection resulted in a decrease in cancer-specific mortality; however, it introduced additional dilemmas and adherence barriers for patients and providers. Methods: Innovations such as biomolecular diagnosis and biosensor-based technology improve the detection and stratification of high-risk patients and might assist in overcoming adherence barriers, hence providing new horizons for better selection of screened populations. Conclusions: In the present manuscript, we discuss some of the dilemmas clinicians are currently facing during the diagnosis and treatment processes. We further highlight the potential benefits of a novel biosensor platform for lung cancer detection during the decision making process surrounding lung cancer.